Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, was selected to receive an Innovations in Clinical Research Award of $486,000 from the Doris Duke Charitable Foundation. The grant will support an innovative research project conducted by Dr. Kohn and Sangamo scientists and titled "Beta-globin Gene Correction in Hematopoietic Stem Cells for Sickle Cell Disease."
Conference Call
Sangamo will host a conference call today, November 4, 2009 at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. The webcast replay will also be available for two weeks after the call. During the conference call, the company will review these results and accomplishments, discuss other business matters, and provide forward-looking guidance with respect to the remainder of 2009.
The conference call dial-in numbers are 877-879-6209 for domestic callers and 719-325-4830 for international callers. The passcode for the call is 4978837. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on November 4, 2009 to midnight ET on November 11, 2009. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820 respectively. The conference ID number for the replay is 4978837.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development
'/>"/>
SOURCE Sangamo BioSciences, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine news :1.
Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference2.
Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives3.
Sangamo BioSciences Reports First Quarter 2009 Financial Results4.
Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference5.
Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 20096.
Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting7.
Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts8.
Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th9.
Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference10.
Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update11.
Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference